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Abstract 
The aim of this study was to assess the clinical characteristics and outcome of patients with 
either primary peritoneal carcinoma (PPC) or ovarian serous carcinoma (OSC) treated with 
paclitaxel plus carboplatin chemotherapy. We retrospectively identified 22 PPC patients and 
55 stage III–IV OSC patients treated between 2002 and 2007. After exploratory laparotomy, 
all patients received paclitaxel and carboplatin every 3 weeks, with the goal of optimal 
cytoreduction. There were no statistically significant differences between the PPC and OSC 
groups with regard to tumor stage, residual tumor after debulking surgery (initial or 
interval), serum cancer antigen (CA) 125 levels at diagnosis, and completion of first-line 
chemotherapy. The progression-free survival (PFS) durations were 12.7 months (95% CI, 6.3–
18.5) in the patients with PPC and 15.9 months (95% CI, 13.3–18.5) in those with OSC (p = 
0.016). However, the median survival durations were 26.5 months (95% CI, 14.6–38.3) in the 
patients with PPC and 38 months (95% CI, 23.8–53.8) in those with OSC (p = 0.188). Survival 
was longer for all patients whose CA125 levels normalized to 26 U/ml during and after 
treatment. Overall survival (OS) of the patients with PPC was similar to that of the patients 
with OSC, suggesting that management for advanced-stage OSC would be similar to that for 
PPC. The combination of optimal debulking with paclitaxel plus carboplatin chemotherapy 
may offer patients the most effective treatment. The CA125 nadir after cytoreductive 
surgery can be considered a prognostic factor for OS and PFS in patients with PPC. 
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Introduction 
Primary peritoneal carcinoma (PPC) is histologically and clinically similar to stage 
III–IV ovarian serous carcinoma (OSC). PPC was first described by Swerdblow in 1959 
[1]. It is a malignancy that spreads widely inside the peritoneal cavity involving mostly 
the omentum with minimal or no ovarian involvement. The following terms are used to 
describe these tumors: peritoneal mesothelioma, peritoneal papillary serous 
carcinoma, serous surface papillary carcinoma, and extraovarian peritoneal serous 
papillary carcinoma. Histopathological, immunohistochemical, and clinical similarities 
have been observed between PPC and serous epithelial ovarian cancer [2]. Recent 
molecular and epidemiological studies, however, have shown some differences 
between these two diseases [3]. The Gynecologic Oncology Group (GOG) has developed 
criteria to better define PPC: (1) the ovaries are normal in size or enlarged by a benign 
process; (2) there is greater involvement in the extraovarian sites than on the surfaces 
of either ovary; (3) microscopically, the ovaries are not involved with the tumor or 
exhibit only serosal or cortical implants of a dimension of less than 5 × 5 mm, and (4) 
the histopathological and cytological characteristics of the tumor are predominantly of 
the serous type. Although the histopathological and clinical features of PPC have been 
described in several reports [2, 3], the behavior of this disease remains obscure. 
Treatment of PPC is based on surgical resection associated with adjuvant 
chemotherapy. The purpose of this study was to compare the clinical findings and 
outcomes of PPC and stage III–IV OSC patients treated with paclitaxel plus carboplatin 
chemotherapy. 
Methods 
The clinical and pathological records of 22 PPC patients and 55 stage III–IV OSC patients who were 
managed between October 2002 and December 2007 at the Nara Medical University were reviewed 
retrospectively. The study was approved by the Institutional Review Board. Pathological diagnosis of 
PPC was based on the inclusionary criteria of GOG for PPC. 
Treatment of both PPC and OSC usually included initial surgery followed by adjuvant systemic 
chemotherapy. All patients received chemotherapy in combination with carboplatin (area under the 
curve, 6) and paclitaxel (180 mg/m2) every 3 weeks after the primary surgery. In some cases, if initial 
surgery was not considered feasible, interval surgery was performed after three cycles of 
chemotherapy. Surgical debulking and staging usually consisted of peritoneal washings, bilateral 
salpingo-oophorectomy, total abdominal hysterectomy, omentectomy, and lymphadenectomy. Pelvic 
and para-aortic lymphadenectomy was included in the standard procedure for patients with good 
medical status at the end of the debulking surgery and with absence of or very small residual disease 
(≤1 cm). In patients with larger residual disease and/or poor medical condition at the end of the 
debulking surgery, lymphadenectomy was omitted. 
The patients with PPC were compared with those with OSC for age at diagnosis, serum cancer 
antigen (CA) 125 levels (U/ml), surgical staging, whether primary or secondary surgery was optimal 
(residual tumor ≤1 cm) or suboptimal (residual tumor >1 cm), date of tumor recurrence or 
progression, and patients’ condition at the last follow-up. Although there is no official surgical staging 
system for PPC, all cases of PPC were considered to be equivalent to FIGO stage III or IV ovarian 
carcinoma. Progression-free survival (PFS) was defined as the number of months in which there was 
no evidence of disease on pelvic examination and computed tomographic (CT) scanning. 
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) 11.0 
software (SPSS Inc., Chicago, Ill., USA). The unpaired Student’s t test for continuous variables and 
either the χ2 or Fisher’s exact test for categorical data were used to evaluate the statistical significance  
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of differences in the clinical characteristics between the two groups. For all statistical tests, the level 
of significance was set at p < 0.05. Survival analysis was performed by the Kaplan-Meier method, and 
statistical significance was determined by the log-rank test. 
Results 
The characteristics of the two groups of patients are shown in table 1. The 
differences between the PPC and OSC patients with regard to median age at diagnosis, 
clinical stage, performance status, pretreatment CA125 level, and CA125 nadir level 
were not significant. The pretreatment CA125 level ranged from 104 to 12,629 U/ml 
(median, 638 U/ml) and from 82 to 71,061 U/ml (median, 1,777 U/ml) in the PPC and 
OSC groups, respectively (p = 0.099). There was no significant statistical difference 
between the two groups for the proportion of the patients with CA125 nadir 
concentrations <26 U/ml (p = 0.945). 
Surgical characteristics of the two groups of patients are detailed in table 2. There 
was no statistically significant difference between the two groups with regard to the 
timing of debulking surgery. Bilateral salpingo-oophorectomy, hysterectomy, and 
omentectomy were performed in all OSC and PPC patients during the debulking 
surgery. Pelvic and para-aortic lymphadenectomies were performed in 14 patients 
(63.7%) with PPC and 40 patients (72.7%) with OSC. Optimal debulking (residual 
tumor ≤1 cm) was achieved in a statistically similar percentage of patients. The median 
number of courses of first-line chemotherapy (total number of courses administered 
before and after debulking surgery in patients who underwent interval debulking 
surgery) was 8 (range, 6–9) in the OSC and PPC patients. 
The median duration of follow-up was 29.7 months (range, 5.1–93.7) and 38.8 
months (range, 3.9–98.7) in the PPC and OSC groups, respectively. The median PFS 
durations were 12.7 months (95% CI, 6.3–19.1) in the patients with PPC and 15.9 
months (95% CI, 13.3–18.5) in those with OSC (p = 0.016). The median overall survival 
(OS) durations were 26.5 months (95% CI, 14.7–38.3) in patients with PPC and 38.8 
months (95% CI, 23.8–53.7) in those with OSC (p = 0.118). 
In the PPC and OSC groups, survival was longer for the patients whose CA125 levels 
normalized to ≤26 U/ml (our institution’s normal range) during and after treatment 
(fig. 1, fig. 2). These results were statistically significant in both groups (p < 0.0001). 
The median survival durations for the patients with PPC and OSC who had CA125 levels 
≤26 IU/ml during and after treatment were 33.6 and 61.5 months and for the patients 
with CA125 levels >26 IU/ml they were 11.9 and 24.4 months, respectively. No 
statistically significant (p > 0.05) differences in median survival were found between 
the PPC and OSC patients. 
Discussion 
The clinical and pathological characteristics of patients with PPC have been 
previously investigated in published series [2, 3]. PPC is diagnosed in approximately 
10% of patients who undergo laparotomy for ovarian carcinoma [4]. It has been 
reported that the incidence of PPC has increased over the last decade [4]. However, the  
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etiology, pathogenesis, cell type of origin, and clinical characteristics of PPC remain 
obscure. Histologically, the predominant subtype of PPC is papillary serous, but others 
have also been reported [4]. The most common symptoms of PPC are abdominal pain, 
distension, and discomfort. Although PPC commonly involves the abdominal and pelvic 
peritoneum, the omentum and diaphragm are also affected, and one of the key 
characteristics of this type of tumor is that it diffusely involves only the peritoneal 
surfaces, with little or no involvement of the ovaries [4]. Consistent with the findings of 
other studies [4], we found that all the patients with PPC had stage III or IV disease at 
diagnosis and elevated serum CA125 levels. 
Treatment of PPC is based on cytoreductive surgery and platinum-based 
chemotherapy. Optimal cytoreduction is the primary goal of the surgical procedure. In 
this study, 12 patients (54.5%) received optimal cytoreductive surgery. The 
chemotherapeutic regimen used for PPC should be similar to that used in ovarian 
carcinoma. Use of platinum-based chemotherapeutic regimens improves patients’ 
survival. Long-term survival can be achieved in some patients using paclitaxel plus 
cisplatin or carboplatin [5]. Dose-dense weekly administration of paclitaxel is another 
strategy to enhance antitumor activity and prolong survival in ovarian cancer patients. 
A dose-dense regimen of paclitaxel once a week plus carboplatin every 3 weeks is 
associated with longer PFS and OS compared with a conventional regimen of paclitaxel 
and carboplatin given every 3 weeks in women with advanced ovarian cancer and PPC 
[6]. Therefore, a dose-dense regimen may be a new treatment option in women with 
PPC. 
The median OS rate reported in the present study (26.5 months) is similar to that 
reported in previous studies [5, 7], in which the median OS varied between 20.0 and 
30.0 months. Optimal cytoreductive surgery, defined as cytoreductive surgery resulting 
in <1.0 cm residual tumors, was achieved in 54.5% of our study population. This rate is 
consistent with the rates of optimal cytoreductive surgery (defined as ≤2.0 cm residual 
tumors), which have been reported to vary between 33 and 69% by other investigators 
[7–9]. Several comparative and case-control studies seem to have suggested that PPC 
and OSC have similar prognoses [4, 10], whereas other series have suggested poorer 
survival in PPC [8]. In our study, PFS was significantly greater in the OSC patients than 
in the PPC patients, although OS was similar in both groups. However, the reason for 
the difference in PFS between the two groups was obscure, and the percentage of 
patients who underwent debulking surgery after neoadjuvant chemotherapy (because 
of massive unresectable disease during initial surgery) was higher in the PPC group 
than in the OSC group (90.9 vs. 70.9%). This may indicate that peritoneal spread is 
more extensive in PPC than in OSC, and we found that PFS is poor in the PPC group. 
However, the percentage of optimal debulking surgery (residual tumor ≤1 cm) was the 
same in both groups. Therefore, further studies are needed to determine the survival 
rates between the two groups. The median follow-up duration in the patients with PPC 
was shorter than that in the patients with OSC, although the difference was not 
significant. This may be related to the tendency toward overall shorter survival in the 
patients with PPC than in patients with OSC. 
The CA125 serum concentration has been established as a tool of great importance 
in the diagnosis of and prognosis for OSC and monitoring of treatment [11]. Several 
reports have recently indicated that it may be possible to define the risk of relapse and 
death by dividing OSC patients that have achieved a complete response after primary  
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treatment into arbitrary groups based on the CA125 nadir [12, 13]. Values ≤10–12 
IU/ml have been associated with increases in PFS [12, 13] and OS [12, 13]. In PPC 
patients, serum CA125 levels are reported to be elevated in most PPC patients [14, 15]. 
In our group of PPC patients, OS was longer in those whose CA125 levels normalized to 
≤26 U/ml during and after treatment. In optimally treated patients with OSC, the CA125 
nadir value is a strong independent prognostic factor. In our study, the CA125 nadir 
was found to be a strong prognostic factor for PPC. However, unlike many retrospective 
studies, our study was limited by the small number and heterogeneity of the included 
patients. Therefore, the significance and utility of the CA125 nadir as a surrogate 
marker of residual disease after primary treatment for PPC needs to be confirmed in 
future clinical trials. 
Conclusion 
Prognosis of the patients with PPC was similar to that of the patients with stage III–
IV OSC. The combination of optimal debulking and paclitaxel plus carboplatin 
chemotherapy may offer the most effective treatment for these patients. The CA125 
nadir after cytoreductive surgery can be considered to be a prognostic factor for OS and 
PFS in patients with PPC. 
 
 
 
Table 1. Patient characteristics 
                Characteristics  PPC (n = 22)  OSC (n = 55)  p 
                Median age, years (range)  .067 (46–75)  .0058 (45–79)  0.166 
Stage, n       
IIIb  .001 (4.5%)  .0002 (3.6%)   
IIIc  .017 (77.3%)  .0036 (65.5%)  0.869 
IV  .004 (18.2%)  .0017 (30.9%)   
Performance status, n       
0–1  .017 (77.3%)  .0043 (78.2%)  0.931 
2  .005 (22.7%)  .0012 (21.8%)   
Median pretreatment CA125, U/ml (range)  .638 (104–12,629)  1,777 (82–71,061)  0.099 
Nadir of CA125 concentration, n       
≤26 U/ml  .016 (72.7%)  .0036 (65.5%)  0.945 
>26 U/ml  .006 (27.3%)  .0019 (34.5%)   
Median follow-up time, months (range)  29.7 (5.1–93.7)  038.8 (3.9–98.7)  0.062 
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Table 2. Patient characteristics 
                Characteristics  PPC (n = 22)  OSC (n = 55)  p 
                Timing of debulking surgery, n 
Initial  2 (9.1%)  16 (29.1%)  0.077 
Interval  20 (90.9%)  39 (70.9%)   
Residual tumor, n       
≤1 cm (optimal)  12 (54.5%)  28 (50.9%)  0.798 
>1 cm (suboptimal)  10 (45.5%)  27 (49.1%)   
                 
 
 
 
 
Fig. 1. Overall survival curve on basis of CA125 nadir levels in PPC groups. 
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Fig. 2. Overall survival curve on basis of CA125 nadir levels in OSC groups. 
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